Apogee Therapeutics price target raised to $116 from $109 at Craig-Hallum

Craig-Hallum raised the firm’s price target on Apogee Therapeutics (APGE) to $116 from $109 and keeps a Buy rating on the shares. Apogee comes out swinging in 2026 with encouraging Phase 1b asthma data for zumilokibart that, in the firm’s view, validate depth/durability and supports a pipeline-in-a-product narrative with a plausible path to every 3-6-month dosing across multiple inflammation and immunology indications. Management plans to announce additional asthma program details later this year and additional Phase 1b data at a medical meeting, Craig-Hallum adds. The firm would lean into POC in asthma and durability as the key takeaway from this data ahead of three atopic dermatitis datasets in 2026 that should further define dose response, durability, and differentiation.